Dallah H1 2025 profit up 21% to SAR 279.8M; Q2 at SAR 124.3M

04/08/2025 Argaam Exclusive

View other reports

Dallah Healthcare Co. reported a net profit of SAR 279.8 million in H1 2025, an increase of 21% from SAR 231.1 million a year earlier.

Financials (M)

Item	6m 2024	6m 2025	Change‬
Revenues	1,549.24	1,895.19	22.3 %
Gross Income	591.09	673.49	13.9 %
Operating Income	278.92	267.65	(4.0 %)
Net Income	231.14	279.82	21.1 %
Average Shares	97.68	101.57	4.0 %
Earnings Per Share before unusual items (Riyals)	2.37	2.13	(10.2 %)
EPS (Riyal)	2.37	2.75	16.4 %

The profit increase is driven by a 22.3% year-on-year (YoY) growth in revenue to SAR 1.89 billion. This was due to the record revenues achieved in the current quarter on improved operational capacity and strategic expansions in existing and acquired medical facilities. This contributed to the continued growth in the number of patients.

The acquisition of Al Salam Medical Services Co., owner of Dallah Hospital Al-Khobar, and Al Ahsa Medical Services Co., owner of Dallah Hospital Al-Ahsa, on March 23, 2025, had a positive impact on revenues. The total revenues of the two hospitals for the current period amounted to approximately SAR 189 million.

Dallah Hospital Al-Khobar and Dallah Hospital Al-Ahsa saw a surge in revenue under Dallah Health's management. The topline increased by 52% YoY (the hospitals' revenues for H1 2024 are not included in Dallah’s earnings as they preceded the acquisition date).

The acquisition of the two hospitals contributed a 37% increase in the group's bed capacity, with the addition of 424 beds (274 beds in Dallah Al-Ahsa Hospital and 150 beds in operation in Dallah Al-Khobar Hospital).

The deal is expected to increase the group's revenues by approximately SAR 500 million throughout 2025 (starting from the acquisition date of March 23, 2025). This growth is expected to continue at high rates in the following years, with increased operating rates at the two hospitals, particularly Dallah Hospital Al-Khobar.

The group's existing medical facilities prior to the acquisition also achieved revenue growth of SAR 157 million, a 10.1% increase YoY.

Following the acquisition of Dallah Hospital Al-Khobar, its net losses reduced by 49% YoY to SAR 23 million.

Net profit before interest, depreciation, amortization, and Zakat for the period rose by 21.3% to SAR 462 million, compared to SAR 381 million in the same period last year.

Current Quarter Comparison (M)

Compared With The

Item	Q2 2024	Q2 2025	Change‬
Revenues	765.18	1,062.43	38.8 %
Gross Income	297.73	375.88	26.3 %
Operating Income	135.70	147.71	8.9 %
Net Income	111.84	124.26	11.1 %
Average Shares	97.68	101.57	4.0 %
Earnings Per Share before unusual items (Riyal)	1.14	1.10	(3.9 %)
EPS (Riyal)	1.14	1.22	6.8 %

Item	Q1 2025	Q2 2025	Change‬
Revenues	832.75	1,062.43	27.6 %
Gross Income	297.61	375.88	26.3 %
Operating Income	119.94	147.71	23.2 %
Net Income	155.56	124.26	(20.1 %)
Average Shares	101.57	101.57	-
Earnings Per Share before unusual items (Riyal)	1.03	1.10	7.3 %
EPS (Riyal)	1.53	1.22	(20.1 %)

Net profit grew 11% in Q2 2025 to SAR 124.3 million from SAR 111.8 million in Q2 2024.

On a sequential basis, net profit fell 20.1% from SAR 155.56 million in Q1 2025.

Total shareholders’ equity, after minority interest, stood at SAR 4.13 billion by June 30, 2025, compared to SAR 3.37 billion a year earlier.

Attached Documents

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2016	285.03	18.6 %	132.53	29.8 %	61.90	56.1 %
Q2 2016	288.35	17.6 %	129.78	28.6 %	59.34	66.2 %
Q3 2016	273.17	22.0 %	122.38	39.2 %	51.80	96.4 %
Q4 2016	316.24	14.4 %	151.01	29.3 %	57.96	1.7 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
Q1 2017	302.75	6.2 %	143.60	8.4 %	85.82	38.6 %
Q2 2017	288.20	0.0 %	130.48	0.5 %	70.86	19.4 %
Q3 2017	295.25	8.1 %	136.77	11.8 %	76.36	47.4 %
Q4 2017	325.87	3.0 %	148.23	(1.8 %)	74.95	29.3 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
Q1 2018	308.59	1.9 %	131.73	(8.3 %)	59.44	(30.7 %)
Q2 2018	273.13	(5.2 %)	92.38	(29.2 %)	19.67	(72.2 %)
Q3 2018	280.94	(4.8 %)	101.37	(25.9 %)	33.44	(56.2 %)
Q4 2018	318.28	(2.3 %)	110.86	(25.2 %)	33.04	(55.9 %)
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
Q1 2019	321.15	4.1 %	120.26	(8.7 %)	41.24	(30.6 %)
Q2 2019	286.00	4.7 %	92.46	0.1 %	18.06	(8.2 %)
Q3 2019	301.34	7.3 %	107.78	6.3 %	30.99	(7.3 %)
Q4 2019	343.60	8.0 %	127.34	14.9 %	64.09	94.0 %
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
Q1 2020	314.61	(2.0 %)	105.76	(12.1 %)	26.42	(35.9 %)
Q2 2020	247.56	(13.4 %)	67.77	(26.7 %)	7.97	(55.9 %)
Q3 2020	350.79	16.4 %	132.62	23.0 %	50.51	63.0 %
Q4 2020	405.30	18.0 %	143.57	12.7 %	40.26	(37.2 %)
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)
Q1 2021	494.67	57.2 %	176.82	67.2 %	72.91	176.0 %
Q2 2021	490.83	98.3 %	168.17	148.1 %	68.57	760.1 %
Q3 2021	544.12	55.1 %	192.46	45.1 %	69.95	38.5 %
Q4 2021	575.57	42.0 %	222.91	55.3 %	116.48	189.4 %
2021	2,105.18	59.7 %	760.36	69.1 %	327.92	162.0 %
Q1 2022	609.40	23.2 %	231.69	31.0 %	109.93	50.8 %
Q2 2022	583.82	18.9 %	212.13	26.1 %	96.68	41.0 %
Q3 2022	600.89	10.4 %	211.47	9.9 %	84.19	20.4 %
Q4 2022	693.88	20.6 %	239.81	7.6 %	101.69	(12.7 %)
2022	2,487.98	18.2 %	895.10	17.7 %	392.49	19.7 %
Q1 2023	716.64	17.6 %	266.79	15.1 %	132.49	20.5 %
Q2 2023	670.42	14.8 %	235.08	10.8 %	87.85	(9.1 %)
Q3 2023	749.83	24.8 %	280.86	32.8 %	130.97	55.6 %
Q4 2023	806.01	16.2 %	295.94	23.4 %	126.50	24.4 %
2023	2,942.90	18.3 %	1,078.67	20.5 %	471.60	20.2 %
Q1 2024	784.06	9.4 %	293.36	10.0 %	143.22	8.1 %
Q2 2024	765.18	14.1 %	297.73	26.7 %	135.70	54.5 %
Q3 2024	847.73	13.1 %	322.99	15.0 %	155.15	18.5 %
Q4 2024	808.76	0.3 %	292.76	(1.1 %)	107.98	(14.6 %)
2024	3,205.73	8.9 %	1,206.84	11.9 %	542.06	14.9 %
Q1 2025	832.75	6.2 %	297.61	1.4 %	119.94	(16.3 %)
Q2 2025	1,062.43	38.8 %	375.88	26.3 %	147.71	8.9 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2015	985.44	14.8 %	407.14	13.5 %	160.78	10.8 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)
2021	2,105.18	59.7 %	760.36	69.1 %	327.92	162.0 %
2022	2,487.98	18.2 %	895.10	17.7 %	392.49	19.7 %
2023	2,942.90	18.3 %	1,078.67	20.5 %	471.60	20.2 %
2024	3,205.73	8.9 %	1,206.84	11.9 %	542.06	14.9 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
Q1 2016	58.07	21.4 %	0.65	(2.02)	60.09	0.67
Q2 2016	54.14	51.0 %	0.60	(3.07)	57.21	0.64
Q3 2016	60.80	127.0 %	0.68	9.42	51.39	0.57
Q4 2016	51.71	(5.3 %)	0.57	(6.00)	57.71	0.64
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
Q1 2017	85.05	46.5 %	0.94	-	85.05	0.94
Q2 2017	69.99	29.3 %	0.78	-	69.99	0.78
Q3 2017	76.82	26.3 %	0.85	-	76.82	0.85
Q4 2017	63.12	22.1 %	0.70	(11.69)	74.81	0.83
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
Q1 2018	58.09	(31.7 %)	0.65	-	58.09	0.65
Q2 2018	18.73	(73.2 %)	0.21	-	18.73	0.21
Q3 2018	32.48	(57.7 %)	0.36	-	32.48	0.36
Q4 2018	32.47	(48.6 %)	0.36	-	32.47	0.36
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
Q1 2019	35.17	(39.5 %)	0.39	-	35.17	0.39
Q2 2019	15.35	(18.1 %)	0.17	-	15.35	0.17
Q3 2019	26.62	(18.1 %)	0.30	-	26.62	0.30
Q4 2019	69.79	115.0 %	0.78	13.39	56.41	0.63
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
Q1 2020	19.24	(45.3 %)	0.21	-	19.24	0.21
Q2 2020	6.99	(54.4 %)	0.08	-	6.99	0.08
Q3 2020	53.78	102.1 %	0.60	16.36	37.42	0.42
Q4 2020	17.11	(75.5 %)	0.19	-	17.11	0.19
2020	97.13	(33.9 %)	1.08	16.36	80.76	0.90
Q1 2021	52.61	173.4 %	0.58	-	52.61	0.58
Q2 2021	47.54	579.9 %	0.53	-	47.54	0.53
Q3 2021	49.85	(7.3 %)	0.55	-	49.85	0.55
Q4 2021	108.60	534.6 %	1.21	10.35	98.25	1.09
2021	258.60	166.3 %	2.87	10.35	248.26	2.76
Q1 2022	82.63	57.1 %	0.92	-	82.63	0.92
Q2 2022	69.52	46.2 %	0.77	-	69.52	0.77
Q3 2022	43.87	(12.0 %)	0.49	-	43.87	0.49
Q4 2022	78.44	(27.8 %)	0.87	-	78.44	0.87
2022	274.46	6.1 %	3.05	-	274.46	3.05
Q1 2023	94.66	14.6 %	0.97	-	94.66	0.97
Q2 2023	53.01	(23.8 %)	0.54	-	53.01	0.54
Q3 2023	98.87	125.4 %	1.01	-	98.87	1.01
Q4 2023	113.65	44.9 %	1.16	-	113.65	1.16
2023	360.12	31.2 %	3.69	-	360.12	3.69
Q1 2024	119.30	26.0 %	1.22	-	119.30	1.22
Q2 2024	111.84	111.0 %	1.14	-	111.84	1.14
Q3 2024	126.15	27.6 %	1.29	-	126.15	1.29
Q4 2024	113.90	0.2 %	1.17	-	113.90	1.17
2024	471.20	30.8 %	4.82	-	471.20	4.82
Q1 2025	155.56	30.4 %	1.53	51.44	104.13	1.03
Q2 2025	124.26	11.1 %	1.22	12.50	111.76	1.10

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
2015	165.06	12.2 %	1.83	13.75	151.31	1.68
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
2020	97.13	(33.9 %)	1.08	16.36	80.76	0.90
2021	258.60	166.3 %	2.87	10.35	248.26	2.76
2022	274.46	6.1 %	3.05	-	274.46	3.05
2023	360.12	31.2 %	3.69	-	360.12	3.69
2024	471.20	30.8 %	4.82	-	471.20	4.82

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	42.51 %	23.29 %	17.20 %
Q2 2016	43.49 %	24.24 %	18.50 %
Q3 2016	44.66 %	25.57 %	19.88 %
Q4 2016	46.07 %	24.94 %	19.47 %
2016	46.07 %	24.94 %	19.47 %
Q1 2017	46.32 %	26.38 %	21.29 %
Q2 2017	46.38 %	27.68 %	22.38 %
Q3 2017	46.73 %	29.19 %	24.08 %
Q4 2017	46.13 %	30.34 %	25.30 %
2017	46.13 %	30.34 %	25.30 %
Q1 2018	44.93 %	28.26 %	22.97 %
Q2 2018	42.33 %	24.50 %	18.99 %
Q3 2018	39.86 %	21.41 %	15.49 %
Q4 2018	36.95 %	18.60 %	12.00 %
2018	36.95 %	18.60 %	12.00 %
Q1 2019	35.60 %	17.66 %	9.96 %
Q2 2019	35.23 %	17.77 %	9.57 %
Q3 2019	35.16 %	17.58 %	8.93 %
Q4 2019	35.77 %	19.73 %	10.66 %
2019	35.77 %	19.73 %	10.66 %
Q1 2020	34.79 %	18.58 %	9.44 %
Q2 2020	33.85 %	18.13 %	9.05 %
Q3 2020	34.50 %	19.13 %	9.55 %
Q4 2020	34.12 %	16.71 %	6.13 %
2020	34.12 %	16.71 %	6.13 %
Q1 2021	34.76 %	18.09 %	7.62 %
Q2 2021	35.67 %	19.32 %	8.88 %
Q3 2021	35.20 %	18.83 %	8.64 %
Q4 2021	36.12 %	21.04 %	11.79 %
2021	36.12 %	21.04 %	11.79 %
Q1 2022	36.72 %	21.66 %	12.54 %
Q2 2022	37.15 %	22.13 %	12.98 %
Q3 2022	37.06 %	22.17 %	12.42 %
Q4 2022	35.98 %	20.37 %	11.03 %
2022	35.98 %	20.37 %	11.03 %
Q1 2023	35.84 %	20.47 %	11.04 %
Q2 2023	35.54 %	19.47 %	10.07 %
Q3 2023	36.12 %	20.16 %	11.48 %
Q4 2023	36.65 %	20.50 %	12.24 %
2023	36.65 %	20.29 %	12.24 %
Q1 2024	36.72 %	20.57 %	12.78 %
Q2 2024	37.61 %	21.64 %	14.29 %
Q3 2024	37.78 %	21.79 %	14.70 %
Q4 2024	37.65 %	21.29 %	14.70 %
2024	37.65 %	21.29 %	14.70 %
Q1 2025	37.21 %	20.55 %	14.01 %
Q2 2025	36.30 %	19.94 %	12.84 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2015	41.32 %	22.03 %	15.35 %
2016	46.07 %	24.94 %	19.47 %
2017	46.13 %	30.34 %	25.30 %
2018	36.95 %	18.60 %	12.00 %
2019	35.77 %	19.73 %	10.66 %
2020	34.12 %	16.71 %	6.13 %
2021	36.12 %	21.04 %	11.79 %
2022	35.98 %	20.37 %	11.03 %
2023	36.65 %	20.29 %	12.24 %
2024	37.65 %	21.29 %	14.70 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	46.50 %	26.86 %	21.08 %
Q2 2016	45.01 %	25.49 %	19.84 %
Q3 2016	44.80 %	24.50 %	18.81 %
Q4 2016	47.75 %	23.08 %	18.25 %
Q1 2017	47.43 %	32.36 %	28.09 %
Q2 2017	45.27 %	30.84 %	24.28 %
Q3 2017	46.32 %	30.89 %	26.02 %
Q4 2017	45.49 %	27.52 %	22.96 %
Q1 2018	42.69 %	24.11 %	18.82 %
Q2 2018	33.82 %	14.42 %	6.86 %
Q3 2018	36.08 %	18.15 %	11.56 %
Q4 2018	34.83 %	17.24 %	10.20 %
Q1 2019	37.45 %	20.42 %	10.95 %
Q2 2019	32.33 %	15.01 %	5.37 %
Q3 2019	35.77 %	17.35 %	8.83 %
Q4 2019	37.06 %	25.11 %	16.42 %
Q1 2020	33.62 %	15.88 %	6.12 %
Q2 2020	27.38 %	12.22 %	2.82 %
Q3 2020	37.81 %	21.04 %	10.67 %
Q4 2020	35.42 %	16.33 %	4.22 %
Q1 2021	35.75 %	20.37 %	10.64 %
Q2 2021	34.26 %	19.51 %	9.69 %
Q3 2021	35.37 %	18.67 %	9.16 %
Q4 2021	38.73 %	25.18 %	17.07 %
Q1 2022	38.02 %	22.74 %	13.56 %
Q2 2022	36.34 %	21.69 %	11.91 %
Q3 2022	35.19 %	19.15 %	7.30 %
Q4 2022	34.56 %	18.22 %	11.30 %
Q1 2023	37.23 %	22.77 %	13.21 %
Q2 2023	35.06 %	17.54 %	7.91 %
Q3 2023	37.46 %	21.82 %	13.19 %
Q4 2023	36.72 %	19.74 %	14.10 %
Q1 2024	37.42 %	22.82 %	15.22 %
Q2 2024	38.91 %	22.24 %	14.62 %
Q3 2024	38.10 %	22.38 %	14.88 %
Q4 2024	36.20 %	17.77 %	14.08 %
Q1 2025	35.74 %	19.81 %	12.50 %
Q2 2025	35.38 %	19.75 %	10.52 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2016	90.00	1.95	1.97	16.15
Q2 2016	90.00	2.15	2.21	15.76
Q3 2016	90.00	2.53	2.48	16.26
Q4 2016	90.00	2.50	2.52	16.85
Q1 2017	90.00	2.80	2.79	17.78
Q2 2017	90.00	2.97	2.93	17.24
Q3 2017	90.00	3.15	3.22	18.05
Q4 2017	90.00	3.28	3.41	18.80
Q1 2018	90.00	2.98	3.11	19.41
Q2 2018	90.00	2.41	2.54	17.98
Q3 2018	90.00	1.92	2.05	18.34
Q4 2018	90.00	1.58	1.58	17.79
Q1 2019	90.00	1.32	1.32	18.07
Q2 2019	90.00	1.28	1.28	16.24
Q3 2019	90.00	1.22	1.22	16.54
Q4 2019	90.00	1.63	1.48	16.91
Q1 2020	90.00	1.46	1.31	16.57
Q2 2020	90.00	1.36	1.21	16.65
Q3 2020	90.00	1.66	1.33	17.25
Q4 2020	90.00	1.08	0.90	19.94
Q1 2021	90.00	1.45	1.27	19.89
Q2 2021	90.00	1.90	1.72	20.42
Q3 2021	90.00	1.86	1.86	20.86
Q4 2021	90.00	2.87	2.76	20.74
Q1 2022	90.00	3.21	3.09	21.70
Q2 2022	90.00	3.45	3.34	22.47
Q3 2022	90.00	3.38	3.27	21.96
Q4 2022	90.00	3.05	3.05	22.11
Q1 2023	97.68	2.93	2.93	32.03
Q2 2023	97.68	2.76	2.76	32.07
Q3 2023	97.68	3.33	3.33	32.64
Q4 2023	97.68	3.69	3.69	32.79
Q1 2024	97.68	3.94	3.94	34.02
Q2 2024	97.68	4.54	4.54	34.51
Q3 2024	97.68	4.82	4.82	34.96
Q4 2024	97.68	4.82	4.82	35.51
Q1 2025	101.57	5.00	4.49	39.98
Q2 2025	101.57	5.12	4.49	40.71

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2015	90.00	1.83	1.68	15.48
2016	90.00	2.50	2.52	16.85
2017	90.00	3.28	3.41	18.80
2018	90.00	1.58	1.58	17.79
2019	90.00	1.63	1.48	16.91
2020	90.00	1.08	0.90	19.94
2021	90.00	2.87	2.76	20.74
2022	90.00	3.05	3.05	22.11
2023	97.68	3.69	3.69	32.79
2024	97.68	4.82	4.82	35.51

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Recurring P/E	Price/book
Q1 2016	28.55	28.22	3.44
Q2 2016	29.68	28.92	4.05
Q3 2016	22.14	22.57	3.44
Q4 2016	28.13	27.92	4.17
Q1 2017	26.99	27.02	4.24
Q2 2017	27.88	28.24	4.81
Q3 2017	25.62	25.09	4.47
Q4 2017	22.81	21.94	3.98
Q1 2018	25.79	24.71	3.96
Q2 2018	29.56	28.04	3.96
Q3 2018	23.83	22.32	2.49
Q4 2018	26.40	26.40	2.34
Q1 2019	34.12	34.12	2.49
Q2 2019	36.29	36.29	2.87
Q3 2019	37.54	37.54	2.76
Q4 2019	26.96	29.67	2.60
Q1 2020	29.56	32.93	2.60
Q2 2020	32.37	36.33	2.65
Q3 2020	32.00	39.93	3.09
Q4 2020	50.46	60.68	2.73
Q1 2021	41.02	46.90	2.99
Q2 2021	47.15	52.14	4.39
Q3 2021	43.03	43.03	3.83
Q4 2021	29.50	30.73	4.09
Q1 2022	35.69	37.01	5.27
Q2 2022	36.23	37.48	5.56
Q3 2022	52.68	54.54	8.12
Q4 2022	54.77	54.77	7.55
Q1 2023	54.60	54.60	5.00
Q2 2023	63.13	63.13	5.44
Q3 2023	44.57	44.57	4.54
Q4 2023	48.45	48.45	5.45
Q1 2024	44.18	44.18	5.12
Q2 2024	35.44	35.44	4.66
Q3 2024	34.72	34.72	4.79
Q4 2024	32.21	32.21	4.39
Q1 2025	25.34	28.20	3.17
Q2 2025	25.52	29.09	3.21

Period	P/E	Recurring P/E	Price/book
2015	28.34	30.92	3.36
2016	28.13	27.92	4.17
2017	22.81	21.94	3.98
2018	26.40	26.40	2.34
2019	26.96	29.67	2.60
2020	50.46	60.68	2.73
2021	29.50	30.73	4.09
2022	54.77	54.77	7.55
2023	48.46	48.46	5.45
2024	31.34	31.34	4.39

Business Segments (Million)

Compared With The

Period	Medical Services	Medicine and Pharmaceutical Products
Q1 2016	276.15	8.88
Q2 2016	277.42	10.93
Q3 2016	265.04	8.13
Q4 2016	307.51	8.73
Q1 2017	239.94	62.81
Q2 2017	229.31	58.90
Q3 2017	235.08	60.17
Q4 2017	241.44	84.43
Q1 2018	236.76	71.84
Q2 2018	205.73	67.39
Q3 2018	218.43	62.50
Q4 2018	228.74	89.55
Q1 2019	239.22	81.93
Q2 2019	210.95	75.06
Q3 2019	232.55	68.79
Q4 2019	259.40	84.20
Q1 2020	227.83	86.77
Q2 2020	166.96	80.60
Q3 2020	260.50	90.30
Q4 2020	309.74	95.55
Q1 2021	378.70	115.97
Q2 2021	374.54	116.29
Q3 2021	412.23	131.88
Q4 2021	472.23	103.34
Q1 2022	470.53	138.87
Q2 2022	475.30	108.52
Q3 2022	438.86	162.03
Q4 2022	547.10	146.77
Q1 2023	530.59	186.05
Q2 2023	513.01	157.40
Q3 2023	518.40	231.43
Q4 2023	597.28	208.74
Q1 2024	574.66	209.40
Q2 2024	550.68	214.50
Q3 2024	628.19	219.55
Q4 2024	467.66	341.10
Q1 2025	581.02	251.74
Q2 2025	818.62	243.82

Period	Medical Services	Medicine and Pharmaceutical Products
2015	925.20	60.24
2016	1,126.12	36.67
2017	945.78	266.30
2018	889.66	291.28
2019	942.12	309.97
2020	965.03	353.22
2021	1,637.71	467.47
2022	1,931.79	556.20
2023	2,159.27	783.63
2024	2,221.19	984.55

Analysts Estimates (Million)

Item	Profit (Expected)	Profit (Actual)	Change	Profit Before Unusual Items	Change
Average	93.13	124.26		111.76

Estimates vs Actual (Million)

Item	Profit (Expected)	Profit (Actual)	Profit Before Unusual Items
U-Capital	106.00	124.26	111.76
SNB Capital	91.00	124.26	111.76
AlJazira Capital	90.50	124.26	111.76
Al Rajhi Capital	85.00	124.26	111.76

Financial Ratios

	Current
Market Cap (M Riyal)	12,696.89
Enterprise Value (EV) (M Riyal)	15,972.86
Shares Outstanding ((M))	101.58
EPS ( Riyal) (TTM)	5.12
Book Value (BV) ( Riyal)	40.71
Par Value ( Riyal)	10.00
Recurring P/E	27.85
P/E (TTM)	24.42
Price/book	3.07
Return on Average Assets (%) (TTM)	6.9
Return on Average Equity (%) (TTM)	13.9
EV/adj EBITDA	22.55
EV/Revenues	4.50

Dallah Healthcare Co. (DALLAH HEALTH)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Dallah H1 2025 profit up 21% to SAR 279.8M; Q2 at SAR 124.3M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2025 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Dallah H1 2025 profit up 21% to SAR 279.8M; Q2 at SAR 124.3M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2025

Revenue by Business Segment (Latest) 2025 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)